Infectious Diseases | Immuno-Oncology | Rare Diseases

 

At Moderna, we believe the world needs novel, innovative approaches to address both known and future infectious disease threats. To that end, we are committed to advancing mRNA-based vaccines and therapies for the prevention and treatment of infectious diseases. 

Moderna’s mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability, which may position our company as a leader in preparing for and responding to infectious disease threats that place millions of people at risk around the world.

There are currently nine prophylactic mRNA vaccines in our development pipeline, with five Phase 1 studies currently underway. These vaccines span a spectrum of infectious diseases, none of which currently has an approved treatment or vaccine.

We are also utilizing our liver therapeutics modality to advance the development of a combination of mRNA-based antibody therapeutics to help prevent human immunodeficiency virus (HIV) infection through a partnership with the Bill & Melinda Gates Foundation.